In this video series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, give an overview of the Estradiol Initiative, an effort to establish transdermal estradiol as a recognized option for androgen deprivation therapy in advanced prostate cancer.
In this Urology Times News Network, recorded at the 2025 SUO Annual Meeting, experts offer commentary on key updates in prostate cancer research.
In this Urology Times News Network, recorded at the 2025 SUO Annual Meeting, experts offer commentary on key updates in bladder cancer research.
In this video series, urologists Karen L. Stern, MD, and Naeem Bhojani, MD, FRCSC, discuss how suction has changed stone surgery, the pros and cons of key techniques like FANS and DISS, and take a closer look at devices such as the CVAC 2.0. They also cover the learning curve, best practices, and where the field is headed next.
In this Urology Times News Network, recorded at the 2025 LUGPA Annual Meeting, experts offer commentary on key updates in prostate cancer research.
In this Urology Times News Network, recorded at the 2025 European Society for Medical Oncology Congress in Berlin, Germany, host Chandler Park, MD, MSc, FACP, interviews Neal D. Shore, MD, FACS, regarding noteworthy prostate and bladder cancer presented at the conference.
This Urology Times RX Review Special Report explores the emergence of subcutaneous immune checkpoint inhibitors in bladder cancer treatment, emphasizing their clinical efficacy, safety, and potential to streamline care. Across the discussion, the series highlights how this innovation can enhance patient experience, improve practice efficiency, and expand access to immunotherapy worldwide.
Rahul Mehan, MD, and Nick Liu, MD, discuss the June 2025 US Food and Drug Administration approval of mitomycin (Zusduri), formerly known as UGN-102, for for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.